Harmony Biosciences Holdings (HRMY) Cash from Financing Activities (2019 - 2026)

Harmony Biosciences Holdings has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$7.2 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$7.2 million, down 1950.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.9 million (down 106.31% YoY), and the FY2025 annual result was -$9.0 million, up 17.71% from the prior year.
• Cash from Financing Activities came in at -$7.2 million for Q1 2026 at Harmony Biosciences Holdings, down from -$3.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $3.4 million in Q1 2023 to a low of -$55.1 million in Q3 2023.
• The 5-year median for Cash from Financing Activities is -$2.7 million (2025), against an average of -$7.4 million.
• Across the five-year window, Cash from Financing Activities surged 11425.0% in 2022 and sank 2787.76% in 2023, its largest moves.
• Harmony Biosciences Holdings' Cash from Financing Activities stood at $2.7 million in 2022, then tumbled by 2113.66% to -$53.5 million in 2023, then soared by 94.88% to -$2.7 million in 2024, then dropped by 10.0% to -$3.0 million in 2025, then sank by 139.4% to -$7.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$7.2 million (Q1 2026), -$3.0 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.